Streetbeat News

Products Services

GILD

NRIX

Nurix Therapeutics is set to present preclinical data on NX-5948 and GS-6791/NX-0479 at the American College of Rheumatology Convergence 2024. NX-5948 is in Phase 1b for B-cell malignancies and IND-enabling studies for autoimmune diseases. GS-6791/NX-0479 is developed in collaboration with Gilead Sciences.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:24 am

VSAT

Viasat has announced enhancements to its satellite network and service model, specifically targeting business aviation in-flight connectivity. Jet ConneX customers will experience improved performance with features like uncapped speeds and expanded capacity.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:22 am

CSTL

Castle Biosciences is set to present new data on its DecisionDx-Melanoma and DecisionDx-UM tests at the International Congress of the Society for Melanoma Research. These tests are designed for patients with cutaneous melanoma and uveal melanoma, respectively.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:21 am

EXAI

Exscientia announced the presentation of three abstracts at the EORTC-NCI-AACR Symposium 2024, highlighting the potential of MALT1 and BTK inhibitors in B-cell malignancies, efficacy of '539 in AML models, and PD biomarkers for LSD1 inhibitor treatment.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:20 am

IRDM

Iridium has announced a collaboration with Nordic Semiconductor to integrate its Iridium NTN Direct service into LTE-M/NB-IoT modules and chipsets. This partnership aims to enhance connectivity solutions.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:20 am

MRNS

Marinus Pharmaceuticals will present additional data from its Phase 3 RAISE trial in refractory status epilepticus and retrospective claims-based data at the Neurocritical Care Society Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:19 am

ZLAB

Zai Lab announced that data from a Phase 1 study of ZL-1310 will be presented at the EORTC-NCI-AACR Symposium. The preliminary results will address the potential of ZL-1310 for treating small cell lung cancer.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:18 am

AS

Amer Sports reported that its revenue growth in Greater China exceeded 60% year-over-year during the seven-day Golden Week period. The company sees significant growth opportunities in China, especially in the outdoor segment, despite economic challenges.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:17 am

OLMA

Olema Pharmaceuticals is set to present multiple posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024), highlighting its research and developments in cancer therapeutics.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:16 am

MRK

Merck is set to present new research findings at IDWeek, showcasing the continued impact of its vaccines and infectious disease portfolio. This presentation could highlight the effectiveness and advancements in Merck's healthcare solutions.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:16 am